Henan Cancer Hospital: Adenocarcinoma trials

The registry lists 12 Adenocarcinoma studies with Henan Cancer Hospital as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 9No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRGRecruitingNCT06774222Phase 2
• Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different GenotypesStatus unknownNCT05608785Phase 1/2
• A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ TrastuzumabStatus unknownNCT05583383Not applicable
• Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaStatus unknownNCT04948125Phase 2
• TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT04891900Not applicable
• Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric CancerStatus unknownNCT04675866Not applicable
• PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric AdenocarcinomaStatus unknownNCT04341857Phase 2
• SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT03950271Phase 2
• Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional AdenocarcinomaStatus unknownNCT03939962Phase 2
• The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / GastroesophagealStatus unknownNCT03451942Phase 2
• Study of Apatinib as the Maintenance Therapy in Advanced Lung AdenocarcinomaStatus unknownNCT03376737Phase 2
• Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung AdenocarcinomaTerminatedNCT02621333Phase 2